iRhythm price target raised to $130 from $110 at Citi

Citi raised the firm’s price target on iRhythm to $130 from $110 and keeps a Neutral rating on the shares. Most Q4 results in medical technology met expectations, which bodes well for the sector, the analyst tells investors in a research note. The analyst says the group has historically "worked" in a beat and raise environment and historically has been "recessionary resistant."